Cacciola R A S, Pujar K, Ilham M A, Puliatti C, Asderakis A, Chavez R
University Hospital of Wales, Renal Transplant Unit, Heath Park, Cardiff, UK CF14 4XQ, United Kingdom.
Transplant Proc. 2008 Dec;40(10):3408-12. doi: 10.1016/j.transproceed.2008.05.085.
Obesity in renal transplantation has proven to affect both patient and graft survival. The scientific community seems to be split into 2 groups: one claims similar outcomes among obese and nonobese, showing only marginally increased postoperative complications; whereas the other group report a higher rate of complications, including graft loss and mortality. These results did not provide sufficient evidence to be applied in practice. In this study we analyzed the outcomes of obese recipients of renal transplant in our institution. One hundred fourteen renal transplantations were performed between January 1993 and December 2003. To estimate the impact of various degrees of obesity, the patients were allocated into 2 cohorts: Group A (body mass index [BMI] 30-34.9) and Group B (BMI 35 and greater). We analyzed patient and donor characteristics. Wound infection rates were similar in the 2 groups. The aggregate Group A and B patient survival rate was 95.6% at 1 year and 93% at 5 years. Graft survival rate was 93.9% at 1 year and 88% at 5 years. However, the analysis of the outcomes in the 2 groups with different degrees of obesity showed that the patient survival rate at 1 year in Group A was 98.9% (1 death) and 95.6% at 5 years (4 deaths). In Group B the patient survival rate at 1 year was 87.5% (3 deaths; P = .007) and at 5 years was 79.2% (P = .006). Graft survival rate in Group A was 98.9% (1 graft loss) at 1 year and 94.5% (5 graft losses) at 5 years; in Group B the graft survival rate was 75% (6 graft loss) at 1 year and 63% (9 graft losses) at 5 years (P < .0001 both at 1 and 5 years). The present study showed that overall obese recipient outcomes were as expected when evaluating the obese as a single group of recipients with a BMI >30. The overall patient and graft survival did not show particularly different results from already published studies claiming similar outcomes. However, this series showed different outcomes when we divided them into 2 groups by BMI. There was a remarkable difference between moderate obese (Group A) and morbid obese (Group B) recipients as regards patient and graft survival. It is possible that the excellent outcome in Group A may be the result of super-selection and stringent cardiovascular risk screening that is implemented for this category of potential recipients. Obese recipients with a BMI of >35 are a high-risk category. Because of the difference in the outcomes of the 2 groups, it does not seem reasonable to address obese recipients as a single group. We believe that obese patients should not be discriminated simply on the basis of the BMI. A strict evaluation should be performed before denying the opportunity to receive a renal transplant to these patients.
事实证明,肾移植中的肥胖会影响患者和移植物的存活。科学界似乎分为两组:一组声称肥胖者和非肥胖者的结果相似,仅显示术后并发症略有增加;而另一组报告并发症发生率更高,包括移植物丢失和死亡率。这些结果没有提供足够的证据应用于实践。在本研究中,我们分析了我院肥胖肾移植受者的结果。1993年1月至2003年12月期间共进行了114例肾移植。为了评估不同程度肥胖的影响,将患者分为两个队列:A组(体重指数[BMI]30 - 34.9)和B组(BMI 35及以上)。我们分析了患者和供体的特征。两组的伤口感染率相似。A组和B组患者的总生存率在1年时为95.6%,5年时为93%。移植物生存率在1年时为93.9%,5年时为88%。然而,对不同肥胖程度的两组结果分析表明,A组患者1年生存率为98.9%(1例死亡),5年生存率为95.6%(4例死亡)。B组患者1年生存率为87.5%(3例死亡;P = 0.007),5年生存率为79.2%(P = 0.006)。A组移植物1年生存率为98.9%(1例移植物丢失),5年生存率为94.5%(5例移植物丢失);B组移植物1年生存率为75%(6例移植物丢失),5年生存率为63%(9例移植物丢失)(1年和5年时P均<0.0001)。本研究表明,在将肥胖者作为BMI>30的单一受者群体进行评估时,肥胖受者的总体结果与预期相符。总体患者和移植物生存率与已发表的声称结果相似的研究相比,没有显示出特别不同的结果。然而,当我们按BMI将它们分为两组时,该系列显示出不同的结果。在患者和移植物存活方面,中度肥胖(A组)和病态肥胖(B组)受者之间存在显著差异。A组的良好结果可能是对这类潜在受者实施超级选择和严格心血管风险筛查的结果。BMI>35的肥胖受者是高危类别。由于两组结果存在差异,将肥胖受者作为一个单一群体对待似乎不合理。我们认为,不应仅仅基于BMI对肥胖患者进行歧视。在拒绝这些患者接受肾移植的机会之前,应进行严格评估。